Market News / Story
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
BusinessWire ·
BusinessWire reports: Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, and the 15-20 National Hospital (l’Hôpital national des 15-20) in Paris today announced the publication of the results of the GS030 PIONEER trial in the prestigious medical journal The New England Journal of…